Mayo Clinic Q&A podcast: COVID-19 and multisystem inflammatory syndrome in children - Scorecard - MDSpire

Mayo Clinic Q&A podcast: COVID-19 and multisystem inflammatory syndrome in children

Children can become ill with COVID-19, and sometimes they develop a rare but serious reaction called multisystem inflammatory syndrome in children (MIS-C).

  • October 9, 2020

Share

Clinical Scorecard: COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C)

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationChildren under 21 years old, particularly those aged 1-14, with emphasis on the average age of 8.
Care Setting

Key Highlights

  • Add a highlight regarding potential long-term effects of MIS-C.

Guideline-Based Recommendations

Diagnosis

  • Include CDC diagnostic criteria for MIS-C.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Children under 21 years old, with a focus on those aged 1-14.

        Treatment strategies may mirror those used for Kawasaki disease.

        Clinical Best Practices

        • Expand management strategies to include corticosteroids and IVIG.

        References

        Original Source(s)

        Mayo Clinic Q&A podcast: COVID-19 and multisystem inflammatory syndrome in children

        • October 9, 2020

        Related Content

        Long COVID as a network disorder: a mechanism-anchored framework for biological stratification and therapeutic targeting

        The latest developments on Ebola, hepatitis B, long Covid

        Postextubation Pneumonia Tops Ventilator Pneumonia

        Older age, male sex, underweight status, reduced activities of daily living, and mild consciousness disturbance were associated with postextubation pneumonia in elective surgical patients.